PT95396B - Processo para a preparacao duma vacina para a proteccao contra a hemofilose suina - Google Patents
Processo para a preparacao duma vacina para a proteccao contra a hemofilose suina Download PDFInfo
- Publication number
- PT95396B PT95396B PT95396A PT9539690A PT95396B PT 95396 B PT95396 B PT 95396B PT 95396 A PT95396 A PT 95396A PT 9539690 A PT9539690 A PT 9539690A PT 95396 B PT95396 B PT 95396B
- Authority
- PT
- Portugal
- Prior art keywords
- toxin
- anatoxin
- process according
- serotype
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 claims abstract description 11
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 10
- 230000002949 hemolytic effect Effects 0.000 claims abstract description 9
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 7
- 241000282898 Sus scrofa Species 0.000 claims abstract description 6
- 239000003053 toxin Substances 0.000 claims description 31
- 231100000765 toxin Toxicity 0.000 claims description 31
- SGNXVBOIDPPRJJ-PSASIEDQSA-N 1-[(1r,6r)-9-azabicyclo[4.2.1]non-4-en-5-yl]ethanone Chemical compound CC(=O)C1=CCC[C@@H]2CC[C@H]1N2 SGNXVBOIDPPRJJ-PSASIEDQSA-N 0.000 claims description 28
- 239000003948 anatoxin Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 18
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 7
- 239000002609 medium Substances 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 241000606750 Actinobacillus Species 0.000 claims 2
- 238000009631 Broth culture Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000006798 recombination Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 108700012359 toxins Proteins 0.000 description 22
- 241000700159 Rattus Species 0.000 description 6
- 241000282887 Suidae Species 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000753 anti-hemolysin Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR898912567A FR2652266B1 (fr) | 1989-09-26 | 1989-09-26 | Vaccin protecteur contre l'hemophilose porcine. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT95396A PT95396A (pt) | 1991-05-22 |
| PT95396B true PT95396B (pt) | 1997-07-31 |
Family
ID=9385815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT95396A PT95396B (pt) | 1989-09-26 | 1990-09-24 | Processo para a preparacao duma vacina para a proteccao contra a hemofilose suina |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0420743B1 (da) |
| JP (1) | JP3169379B2 (da) |
| AT (1) | ATE189609T1 (da) |
| AU (1) | AU635349B2 (da) |
| CA (1) | CA2035474C (da) |
| DD (1) | DD297560A5 (da) |
| DE (2) | DE69033454T2 (da) |
| DK (1) | DK0420743T3 (da) |
| ES (1) | ES2143456T3 (da) |
| FR (1) | FR2652266B1 (da) |
| GR (1) | GR3033151T3 (da) |
| PT (1) | PT95396B (da) |
| WO (1) | WO1991004747A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5417971A (en) * | 1991-10-22 | 1995-05-23 | University Of Saskatchewan | Vaccines for Actinobacillus pleuropneumoniae |
| CA2170839A1 (en) * | 1995-03-01 | 1996-09-02 | Janet Macinnes | Bacterial preparations, method for producing same, and their use as vaccines |
| US5925354A (en) * | 1995-11-30 | 1999-07-20 | Michigan State University | Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK138379A (da) * | 1979-04-04 | 1980-10-05 | Nordisk Droge & Kemikalie | Vaccine imod pleuropneumonia (ondartet lungesyge) hos svin dens anvendelse samt fremgangsmaade og substat til dyrkning specielt aerob fermentering af mikroorganismen haemophilus pleuropneumoniae |
| IE59079B1 (en) * | 1986-11-05 | 1994-01-12 | Oldcastle Veterinary Research | A method of preparing an autogenous vaccine |
-
1989
- 1989-09-26 FR FR898912567A patent/FR2652266B1/fr not_active Expired - Lifetime
-
1990
- 1990-09-21 DD DD90344141A patent/DD297560A5/de unknown
- 1990-09-24 PT PT95396A patent/PT95396B/pt not_active IP Right Cessation
- 1990-09-25 DE DE69033454T patent/DE69033454T2/de not_active Expired - Lifetime
- 1990-09-25 WO PCT/FR1990/000688 patent/WO1991004747A1/fr not_active Ceased
- 1990-09-25 CA CA002035474A patent/CA2035474C/en not_active Expired - Lifetime
- 1990-09-25 EP EP90402639A patent/EP0420743B1/fr not_active Expired - Lifetime
- 1990-09-25 JP JP51391990A patent/JP3169379B2/ja not_active Expired - Lifetime
- 1990-09-25 DK DK90402639T patent/DK0420743T3/da active
- 1990-09-25 ES ES90402639T patent/ES2143456T3/es not_active Expired - Lifetime
- 1990-09-25 AU AU65230/90A patent/AU635349B2/en not_active Expired
- 1990-09-25 DE DE2001199019 patent/DE10199019I1/de active Pending
- 1990-09-25 AT AT90402639T patent/ATE189609T1/de not_active IP Right Cessation
-
2000
- 2000-04-04 GR GR20000400844T patent/GR3033151T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2035474A1 (en) | 1991-03-27 |
| FR2652266B1 (fr) | 1994-08-12 |
| DK0420743T3 (da) | 2000-06-19 |
| DE69033454T2 (de) | 2000-06-21 |
| EP0420743A1 (fr) | 1991-04-03 |
| EP0420743B1 (fr) | 2000-02-09 |
| JPH04502018A (ja) | 1992-04-09 |
| GR3033151T3 (en) | 2000-08-31 |
| ATE189609T1 (de) | 2000-02-15 |
| FR2652266A1 (fr) | 1991-03-29 |
| WO1991004747A1 (fr) | 1991-04-18 |
| ES2143456T3 (es) | 2000-05-16 |
| DE10199019I1 (de) | 2001-05-23 |
| JP3169379B2 (ja) | 2001-05-21 |
| AU6523090A (en) | 1991-04-28 |
| AU635349B2 (en) | 1993-03-18 |
| CA2035474C (en) | 2002-12-03 |
| DD297560A5 (de) | 1992-01-16 |
| DE69033454D1 (de) | 2000-03-16 |
| PT95396A (pt) | 1991-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nunoya et al. | Occurrence of acute infectious bursal disease with high mortality in Japan and pathogenicity of field isolates in specific-pathogen-free chickens | |
| US9662380B2 (en) | C. perfringens alpha toxoid vaccine | |
| ES2446984T3 (es) | Vacuna contra Escherichia coli enterohemorrágica | |
| FI81262C (fi) | Foerfarande foer isolering av ett med adenylat-cyklas-aktivitet associerat antigenpreparat ur bakterien bordetella pertussis. | |
| US5648081A (en) | Actinobacillus pleuropneumoniae subunit vaccine | |
| FR2726472B1 (fr) | Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin | |
| FI120149B (fi) | Ei tyypittävissä olevan Haemophilus influenzaen puhdistettu P5 proteiini rokotteena ei tyypittävissä olevalle Haemophilus influenzae -kannalle | |
| HU211829A9 (en) | Haemophilus paragallinarum vaccine | |
| US4702910A (en) | Common antigen (PSC-A) to Pseudomonas aeruginosa which acts as an agent for pretecting Pseudomonas aeruginosa infection | |
| NZ216267A (en) | Vaccine production by treatment of pertussis toxin with a carbodiimide | |
| PT95396B (pt) | Processo para a preparacao duma vacina para a proteccao contra a hemofilose suina | |
| Lopez-Merino et al. | Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances | |
| US20250099565A1 (en) | Clostridium chauvoei vaccine and method of making | |
| US4857318A (en) | Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis | |
| US6124432A (en) | Process for purifying dermonecrotic toxin produced by Bordetella and toxoid | |
| KR100191487B1 (ko) | 돼지헤모필로시스에 대한 예방백신 | |
| US5114712A (en) | Common antigen (PSC-A) to Pseudomonas aeruginosa which acts as an agent for protecting Pseudomonas aeruginosa infection | |
| RU2191599C1 (ru) | Ассоциированная вакцина для профилактики сибирской язвы и некробактериоза животных | |
| JPWO1995034322A1 (ja) | ボルデテラ属菌産生壊死毒素の精製方法およびトキソイド | |
| JP7281208B2 (ja) | ＳｓｅＪタンパク質を用いたサルモネラワクチン | |
| JP3270473B2 (ja) | パスツレラ・マルトサイダ・トキソイドワクチン | |
| JPS63501950A (ja) | 下痢治療用組成物 | |
| MXPA96004262A (en) | Antigens of pasteurellaceae and vaccines related |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Laying open of patent application |
Effective date: 19910122 |
|
| FG3A | Patent granted, date of granting |
Effective date: 19970415 |
|
| PD3A | Change of proprietorship | ||
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20120416 |